Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBITDA Margin (2016 - 2025)

Voyager Therapeutics' EBITDA Margin history spans 11 years, with the latest figure at 178.67% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 37662.0% year-over-year to 178.67%; the TTM value through Dec 2025 reached 295.44%, down 17306.0%, while the annual FY2025 figure was 295.44%, 21374.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 178.67% at Voyager Therapeutics, up from 207.41% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1516.65% in Q4 2022 and bottomed at 3252.89% in Q1 2022.
  • The 5-year median for EBITDA Margin is 335.7% (2021), against an average of 599.48%.
  • The largest annual shift saw EBITDA Margin crashed -292005bps in 2022 before it skyrocketed 333538bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 20.3% in 2021, then skyrocketed by 7371bps to 1516.65% in 2022, then plummeted by -96bps to 62.84% in 2023, then crashed by -984bps to 555.29% in 2024, then skyrocketed by 68bps to 178.67% in 2025.
  • Per Business Quant, the three most recent readings for VYGR's EBITDA Margin are 178.67% (Q4 2025), 207.41% (Q3 2025), and 642.38% (Q2 2025).